

Cefabactin 250 mg tablets for dogs and cats

Authorised

- Cefalexin monohydrate

Product identification

Medicine name:

Cefabactin 250 mg tablets for dogs and cats

Active substance:

Cefalexin monohydrate

Target species:

Cat

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Cefalexin monohydrate

262.50 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01DB01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Denmark

Available in:

Denmark

Package description:

Cardboard box of 9 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 6 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 4 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 3 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 25 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 2 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 8 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 7 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 5 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 10 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box of 1 blister (Aluminium - PVC/PE/PVDC) of 10 tablets

Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Le Vet. Beheer B.V.

Marketing authorisation date:

31/08/2016

Manufacturing sites for batch release:

Lelypharma B.V.

Responsible authority:

Danish Medicines Agency

Authorisation number:

56260

Date of authorisation status change:

31/08/2016

Reference member state:

Netherlands

Procedure number:

NL/V/0201/002

Concerned member states:

Austria Belgium Croatia Cyprus Czechia Denmark Estonia Finland France
Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.